EMA-话题@MedSci

#EMA#

580篇内容 | 2473人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1317554, encodeId=087e131e554b8, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Journal of Clinical Oncology：Bemarituzumab治疗晚期胃食管腺癌的I期研究, objectType=article, longId=190022, objectId=7727190022fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7727190022fc, replyNumber=0, likeNumber=120, createdTime=2020-03-16, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7727190022fc, moduleTitle=Journal of Clinical Oncology：Bemarituzumab治疗晚期胃食管腺癌的I期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7727190022fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317553, encodeId=f3a8131e55322, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=颅内Castleman病一例, objectType=article, longId=189999, objectId=d91818999998, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d91818999998, replyNumber=0, likeNumber=50, createdTime=2020-03-16, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d91818999998, moduleTitle=颅内Castleman病一例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d91818999998)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317552, encodeId=3f4f131e552cf, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet haematol：Enasidenib治疗IDH2突变型骨髓增生异常综合征, objectType=article, longId=189592, objectId=c3fe18959242, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3fe18959242, replyNumber=0, likeNumber=17, createdTime=2020-03-10, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3fe18959242, moduleTitle=Lancet haematol：Enasidenib治疗IDH2突变型骨髓增生异常综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3fe18959242)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317551, encodeId=f0ba131e551b1, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet haematol：遗传性I型抗凝血酶缺乏症女性发生妊娠相关静脉血栓栓塞和产科并发症的风险, objectType=article, longId=189140, objectId=5f6a189140d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f6a189140d8, replyNumber=0, likeNumber=62, createdTime=2020-03-03, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f6a189140d8, moduleTitle=Lancet haematol：遗传性I型抗凝血酶缺乏症女性发生妊娠相关静脉血栓栓塞和产科并发症的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f6a189140d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317550, encodeId=1fa1131e55021, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：过去十年，结外自然杀伤T细胞淋巴瘤的治疗进展, objectType=article, longId=189131, objectId=df8e18913157, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df8e18913157, replyNumber=0, likeNumber=60, createdTime=2020-03-03, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df8e18913157, moduleTitle=Lancet Haematol：过去十年，结外自然杀伤T细胞淋巴瘤的治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df8e18913157)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317549, encodeId=ffb1131e5490f, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=2020 EMAS/IGCS立场声明：妇科癌症后绝经期管理—聚焦围绝经期综合征和骨质疏松, objectType=article, longId=188621, objectId=7df218862128, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7df218862128, replyNumber=0, likeNumber=15, createdTime=2020-02-24, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7df218862128, moduleTitle=2020 EMAS/IGCS立场声明：妇科癌症后绝经期管理—聚焦围绝经期综合征和骨质疏松, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7df218862128)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317548, encodeId=ea55131e54874, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet haematol：Ropeginterferon alfa-2b对比羟基脲用于真性红细胞增多症的长期疗效！, objectType=article, longId=187425, objectId=b82918e4252e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b82918e4252e, replyNumber=0, likeNumber=66, createdTime=2020-02-06, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b82918e4252e, moduleTitle=Lancet haematol：Ropeginterferon alfa-2b对比羟基脲用于真性红细胞增多症的长期疗效！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b82918e4252e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317547, encodeId=cfbd131e547f4, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet haematol：硼替佐米治疗特发性多中心Castleman病的长期安全性, objectType=article, longId=187424, objectId=563618e4243b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=563618e4243b, replyNumber=0, likeNumber=76, createdTime=2020-02-06, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=563618e4243b, moduleTitle=Lancet haematol：硼替佐米治疗特发性多中心Castleman病的长期安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=563618e4243b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317546, encodeId=3c7f131e546c1, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：抗胸腺蛋白抗体联合标准GVHD预防疗法可明显改善非亲缘供体移植血液恶性肿瘤患者的预后, objectType=article, longId=187105, objectId=5db718e105b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5db718e105b1, replyNumber=0, likeNumber=61, createdTime=2020-02-03, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5db718e105b1, moduleTitle=Lancet Haematol：抗胸腺蛋白抗体联合标准GVHD预防疗法可明显改善非亲缘供体移植血液恶性肿瘤患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5db718e105b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317545, encodeId=918f131e545bf, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=欧洲药品管理局（EMA）授予EHP-102治疗亨廷顿氏病的孤儿药资格, objectType=article, longId=187027, objectId=74ee18e02744, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74ee18e02744, replyNumber=0, likeNumber=70, createdTime=2020-02-01, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74ee18e02744, moduleTitle=欧洲药品管理局（EMA）授予EHP-102治疗亨廷顿氏病的孤儿药资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74ee18e02744)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317544, encodeId=a8c6131e54494, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：5种一线晚期霍奇金淋巴瘤治疗方案成本效益评估, objectType=article, longId=186274, objectId=72631862e452, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72631862e452, replyNumber=0, likeNumber=67, createdTime=2020-01-16, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72631862e452, moduleTitle=Lancet Haematol：5种一线晚期霍奇金淋巴瘤治疗方案成本效益评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72631862e452)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317543, encodeId=b331131e54347, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haemat：Shwachman-Diamond综合征合并MDS或AML患者的临床特征及预后, objectType=article, longId=185331, objectId=f042185331ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f042185331ad, replyNumber=0, likeNumber=139, createdTime=2019-12-29, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f042185331ad, moduleTitle=Lancet Haemat：Shwachman-Diamond综合征合并MDS或AML患者的临床特征及预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f042185331ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317542, encodeId=a12f131e5429d, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haemat：acalabrutinib治疗Waldenström巨球蛋白血症, objectType=article, longId=185329, objectId=0ab6185329f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ab6185329f3, replyNumber=0, likeNumber=66, createdTime=2019-12-29, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ab6185329f3, moduleTitle=Lancet Haemat：acalabrutinib治疗Waldenström巨球蛋白血症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ab6185329f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317541, encodeId=24d1131e541e7, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haemat：极光激酶A抑制剂alisertib治疗高危型急性粒细胞白血病, objectType=article, longId=184769, objectId=59fd184e6932, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59fd184e6932, replyNumber=0, likeNumber=83, createdTime=2019-12-15, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59fd184e6932, moduleTitle=Lancet Haemat：极光激酶A抑制剂alisertib治疗高危型急性粒细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59fd184e6932)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317540, encodeId=2b0a131e5404c, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haemat：超声加速导管溶栓预防血栓后综合征, objectType=article, longId=184623, objectId=16c518462376, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16c518462376, replyNumber=0, likeNumber=52, createdTime=2019-12-13, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16c518462376, moduleTitle=Lancet Haemat：超声加速导管溶栓预防血栓后综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16c518462376)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317539, encodeId=c130131e5399d, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Zotiraciclib治疗胶质母细胞瘤被FDA和EMA授予孤儿药称号, objectType=article, longId=184383, objectId=59e518438304, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59e518438304, replyNumber=0, likeNumber=69, createdTime=2019-12-09, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59e518438304, moduleTitle=Zotiraciclib治疗胶质母细胞瘤被FDA和EMA授予孤儿药称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59e518438304)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317538, encodeId=26a7131e53895, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet haemat：3期试验：利伐沙班治疗静脉血栓栓塞儿童的临床预后和安全性, objectType=article, longId=182776, objectId=6513182e7613, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6513182e7613, replyNumber=0, likeNumber=66, createdTime=2019-11-11, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6513182e7613, moduleTitle=Lancet haemat：3期试验：利伐沙班治疗静脉血栓栓塞儿童的临床预后和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6513182e7613)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317537, encodeId=910c131e537ed, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：新诊断MM诱导治疗反应深度不佳者强化治疗可进一步改善结果, objectType=article, longId=182770, objectId=81ec182e7056, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81ec182e7056, replyNumber=0, likeNumber=76, createdTime=2019-11-11, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81ec182e7056, moduleTitle=Lancet Haematol：新诊断MM诱导治疗反应深度不佳者强化治疗可进一步改善结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81ec182e7056)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317536, encodeId=9362131e5363e, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：产前治疗or产后治疗，霍奇金淋巴瘤孕妇患者及新生儿的生存预后有什么不同？, objectType=article, longId=182768, objectId=5572182e688d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5572182e688d, replyNumber=0, likeNumber=71, createdTime=2019-11-11, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5572182e688d, moduleTitle=Lancet Haematol：产前治疗or产后治疗，霍奇金淋巴瘤孕妇患者及新生儿的生存预后有什么不同？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5572182e688d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317535, encodeId=336e131e535be, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=基于阳性III期结果，EMA已接受将Bratovi和Mektovi联合用于转移性结直肠癌治疗的申请, objectType=article, longId=182599, objectId=86501825990a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86501825990a, replyNumber=0, likeNumber=53, createdTime=2019-11-09, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86501825990a, moduleTitle=基于阳性III期结果，EMA已接受将Bratovi和Mektovi联合用于转移性结直肠癌治疗的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86501825990a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

EMA

2020-05-29

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Journal of Clinical Oncology：Bemarituzumab治疗晚期胃食管腺癌的I期研究

2020-03-16

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

颅内Castleman病一例

2020-03-16

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet haematol：Enasidenib治疗IDH2突变型骨髓增生异常综合征

2020-03-10

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet haematol：遗传性I型抗凝血酶缺乏症女性发生妊娠相关静脉血栓栓塞和产科并发症的风险

2020-03-03

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：过去十年，结外自然杀伤T细胞淋巴瘤的治疗进展

2020-03-03

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

2020 EMAS/IGCS立场声明：妇科癌症后绝经期管理—聚焦围绝经期综合征和骨质疏松

2020-02-24

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet haematol：Ropeginterferon alfa-2b对比羟基脲用于真性红细胞增多症的长期疗效！

2020-02-06

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet haematol：硼替佐米治疗特发性多中心Castleman病的长期安全性

2020-02-06

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：抗胸腺蛋白抗体联合标准GVHD预防疗法可明显改善非亲缘供体移植血液恶性肿瘤患者的预后

2020-02-03

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

欧洲药品管理局（EMA）授予EHP-102治疗亨廷顿氏病的孤儿药资格

2020-02-01

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：5种一线晚期霍奇金淋巴瘤治疗方案成本效益评估

2020-01-16

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haemat：Shwachman-Diamond综合征合并MDS或AML患者的临床特征及预后

2019-12-29

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haemat：acalabrutinib治疗Waldenström巨球蛋白血症

2019-12-29

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haemat：极光激酶A抑制剂alisertib治疗高危型急性粒细胞白血病

2019-12-15

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haemat：超声加速导管溶栓预防血栓后综合征

2019-12-13

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Zotiraciclib治疗胶质母细胞瘤被FDA和EMA授予孤儿药称号

2019-12-09

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet haemat：3期试验：利伐沙班治疗静脉血栓栓塞儿童的临床预后和安全性

2019-11-11

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：新诊断MM诱导治疗反应深度不佳者强化治疗可进一步改善结果

2019-11-11

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：产前治疗or产后治疗，霍奇金淋巴瘤孕妇患者及新生儿的生存预后有什么不同？

2019-11-11

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

基于阳性III期结果，EMA已接受将Bratovi和Mektovi联合用于转移性结直肠癌治疗的申请

2019-11-09

科室
- - 订阅+
  - 更多科室
工具
服务